<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152512</url>
  </required_header>
  <id_info>
    <org_study_id>2018/1402-31/1</org_study_id>
    <nct_id>NCT04152512</nct_id>
  </id_info>
  <brief_title>Quality of Life, Unmet Needs and Satisfaction With Care After Vulvar Cancer</brief_title>
  <acronym>PROVE</acronym>
  <official_title>Quality of Life, Specific Needs and Satisfaction With Care After Treatment for Vulvar Cancer - a Prospective, Longitudinal Swedish Nationwide Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, longitudinal Swedish multi-center study is to assess the quality
      of life, treatment-related morbidity, unmet needs and satisfaction with care after treatment
      for vulvar cancer, evaluated by a validated questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      Information about:

        -  General and vulvar-cancer-specific quality of life before and after any treatment for
           newly diagnosed vulvar cancer

        -  Treatment-related morbidity after any treatment for newly diagnosed vulvar cancer

        -  Unmet needs of patients with newly diagnosed vulvar cancer

        -  Satisfaction with care after any treatment for newly diagnosed vulvar cancer in Sweden.

      OUTLINE:

      The study is planned as a prospective, longitudinal multi-centre study in Sweden. Since 2017,
      the treatment of vulvar cancer patients has been accredited to four tertiary referral
      university hospitals in Sweden; the Sahlgrenska University hospital in Gothenburg, the
      Linköping University hospital, the Skåne University hospital in Lund and the Karolinska
      University hospital in Stockholm.

      150 patients are estimated for inclusion during a time frame of about 18 months.

      Eligible patients will be asked to complete a validated questionnaire at different points of
      time (before and after treatment). Calculating a response rate of about 50% - 60%, this will
      result in at least 80 completed questionnaires.

      The questionnaires consist of the following parts:

        -  European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-C30

        -  European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-VU-34
           (Vulva-specific module)

        -  Hospital Depression and Anxiety Scale (HADS)

        -  Supportive Care Needs Survey Short Form, excerpt (SCNS-SF34)

        -  European Organisation for Research and Treatment of Cancer (EORTC)-PATSAT (Patient
           Satisfaction), excerpt

        -  Demographic data

        -  25 self-constructed (and validated) questions

      RESULTS:

      Results are expected to be available in 2021.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global quality of life</measure>
    <time_frame>1 year after end of treatment</time_frame>
    <description>Measured by the European Organisation of Research and Treatment of Cancer (EORTC)-QLQ-C30-questionnaire.
Measurement on a scale between 0-and 100. Higher values represent better quality of life. A change of at least 5-8 points is regarded as clinically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vulvar-cancer-specific quality of life</measure>
    <time_frame>1 year after end of treatment</time_frame>
    <description>Measured by the EORTC-QLQ-VU34-questionnaire. Higher values represent higher quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with Care</measure>
    <time_frame>3--4 months after end of treatment</time_frame>
    <description>Measured by EORTC-PATSAT-questionnaire. Higher score represent higher satisfaction with care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression and anxiety</measure>
    <time_frame>1 year after end of treatment.</time_frame>
    <description>Measured by the Hospital Anxiety and Depression Index (HADS)-questionnaire. Higher scores represent more depression and anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unmet needs</measure>
    <time_frame>3-4 months after end of treatment.</time_frame>
    <description>Measured by the Supportive Care Needs Survey-Short Form (SCNS-SF)-34-questionnaire. Higher scores represent higher needs.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Vulvar Cancer</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Whole Cohort</arm_group_label>
    <description>Whole cohort administration of questionnaire at 7 times</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire administration</intervention_name>
    <description>Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment</description>
    <arm_group_label>Whole Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with newly diagnosed invasive vulvar cancer in Sweden during the study time frame.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of vulvar cancer, all stages, all planned treatments

          -  Informed consent

        Exclusion Criteria:

          -  Disability to understand and complete the questionnaire due to language difficulties,
             severe psychiatric illness or dementia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Zach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Zach, MD</last_name>
    <phone>+46851775922</phone>
    <email>diana.zach@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angelique Floter Radestad, PhD</last_name>
    <email>angelique.floter-radestad@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms Lan</state>
        <zip>17776</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Zach, MD</last_name>
      <phone>+46851775922</phone>
      <email>diana.zach@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Angelique Floter Radestad, PhD</last_name>
      <email>angelique.floter-radestad@sll.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Stenstrom Bohlin, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linkopings University Hospital</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preben Kjoelhede, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skanes University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Moberg, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Diana Zach</investigator_full_name>
    <investigator_title>MD, senior consultant</investigator_title>
  </responsible_party>
  <keyword>Questionnaire</keyword>
  <keyword>EORTC QLQ C30 + VU34</keyword>
  <keyword>Hospital Depression and Anxiety Scale</keyword>
  <keyword>EORTC-PATSAT</keyword>
  <keyword>Supportive Care Needs Survey Short Form</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

